QI
RETA

QS Investors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

QS Investors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,174
Closed -$808K – 1603
2020
Q2 		$808K Hold
5,174
– – 0.01% 789
2020
Q1 		$747K Hold
5,174
– – 0.01% 741
2019
Q4 		$1.07M Buy
+5,174
New +$944K 0.01% 763

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

QS Investors's RETA Position: Q3 2020 in Review

QS Investors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 5,174 shares — an estimated $808K sold.

QS Investors first reported a position in RETA in Q4 2019 and held it in 3 quarters. The position peaked at $1.07M in Q4 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

  • QS Investors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
  • QS Investors sold 5,174 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $808K.
  • QS Investors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 3 quarters.
  • QS Investors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.07M in Q4 2019.
  • 186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.